



Sunday, January 23, 2005

Evening Session

Organic Synthesis in Non-classical Media, Michael VanNieuwenhze, University of California, San Diego, Program Chair

Paul Grieco, Montana State University – Organic Synthesis in Water and Other Polar Media: An Overview

Hartmuth Kolb, The Scripps Research Institute - 'In Situ' Click Chemistry: Enzyme Inhibitors Made to Their Own Specifications

Shu Kobayashi, Tokyo University – Lewis Acid Catalysis in Aqueous Media

Monday, January 24, 2005

Morning Session

Blockbuster Drug Symposium: Sponsored by Celgene, Les Mitscher, University of Kansas, Program Chair

Andy Bell, Pfizer Global Research & Development - The Viagra Story

Dale Kempf, Abbott Laboratories - The Kaletra-Ritonavir Story

David Wustrow, Pfizer Global Research & Development - The Neurontin Story

Evening Session

Cascade Chemistry, Victor Snieckus, Queen's University, Program Chair

Victor Snieckus, Cascade Chemistry Reactions: An Overview

Richard Heck, Cobalt and Palladium Reagents in Organic Synthesis: The Discovery and the Early Years

Masahiro Miura, Osaka University - Transition Metal Catalyzed Sequential Coupling via C-H Bond Cleavage

Tom Kieboom, Leiden University - Concepts of Nature in Organic Synthesis: Cascade Catalysis and Multistep Conversions in Concert

Ei-ichi Negishi, Purdue University - Tandem and Cascade Carbon-Carbon Bond-Forming Processes Catalyzed by Pd and Zr Complexes

Tuesday, January 25, 2005

Morning Session

Solid-supported Reagents, Tony Barrett, Imperial College, Program Chair

David Bergbreiter, Texas A&M University - Soluble Polymers as Easily Separable Supports in Synthesis and Catalysis

Paul Hanson, University of Kansas - ROM-Polymerization Strategies for Facilitated Synthesis

Steve Ley, Cambridge University – Development of New Methods for Organic Synthesis

John Parlow, Pfizer Global Research & Development – Polymer-Assisted Solution-Phase (PASP) Chemical Library Synthesis and its Application on the Tissue Factor VIIa Project

Evening Poster Session, Bryan Norman, Eli Lilly & Company, Program Chair

Wednesday, January 26, 2005

Morning Session

General Oral Papers I, Dennis Dean, Merck Research Labs, Program Chair

Bryan Norman, Eli Lilly & Company – Benzopyrans are selective ER β agonists for use in the treatment of prostatic diseases

Wayne Brouillette, University of Alabama at Birmingham – Design and development of low toxicity UAB-rexinoids for breast cancer chemoprevention

Robert Meissner, Merck Research Laboratories, - In vitro and In vivo of a ketone-containing $\alpha_v\beta_3$ integrin antagonist for the treatment for osteoporosis

William Kinney, Johnson & Johnson – Computational and pharmacokinetic studies directed at understanding the differences in oral bioavailability seen between closely related $\alpha_v\beta_3$ integrin antagonists

Robert Fecik, University of Minnesota – Synthesis of immunomodulatory macrolides for cystic fibrosis

Katherina Leftheris, Bristol-Myers Squibb – Progression of a novel class of orally active p38 map kinase inhibitors

Axel Neffe, University of Canterbury – Synthesis and modelling studies of peptidomimetic aldehydes related to a cataract preventing calpain inhibitor

Shawn Stachel, Merck Research Laboratories – Structure-based design of a series of potent and selective cell permeable inhibitors of human β -secretase

Keynote Address

Dr. Chris Lipinski, Pfizer Global Research & Development - Chemistry quality and the medicinal chemistry - biology interface

Thursday, January 27, 2005

Morning Session

Protein Conformational Plasticity in Drug Design, Dan Flynn, Deciphera Pharmaceuticals, LLC, Program Chair

Robert McDowell, Sunesis, Inc. - Drug Discovery at Adaptive Signaling Interfaces

Betsy Goldsmith, University of Texas Southwestern Medical Center, Dallas – Binding sites and conformational changes in protein kinases

Tim Willson, GlaxoSmithKline – Exploiting Plasticity in Nuclear Receptor Drug Discovery

Steven LaPlante, Boehringer-Ingelheim – Exploiting ligand and receptor adaptability in antiviral drug design

Evening Session

Small Molecule Modulation of Protein-Protein Interactions, Peter Toogood, Pfizer Global Research & Development, Program Chair

Dale Boger, The Scripps Research Institute – Targeting protein-protein and protein-DNA interaction using solution phase combinatorial chemistry

Lance Stewart, deCODE Genetics, Inc. – The Poisoning of Human Topoisomerase I by Structurally Diverse Anticancer Compounds and Various Insults to DNA

Jim Wells, Sunesis, Inc. - Challenges for Drug Discovery at Protein/Protein Interfaces

David Rees, Astex Technology Ltd. - Starting Small and Strong: Fragment Based Drug Discovery

Friday, January 28, 2005

Morning Session

General Oral Papers II, Philippe Nantermet, Merck Research Labs, Program Chair

Neville Anthony, Merck Research Laboratories – Development of a potent HIV-1 integrase inhibitor with a unique resistance profile

Charles Didier, Imperial College – Double oxidation of tryptophanes: Synthesis of the potent anthelmintic pyrrolobenzoxazine CJ-12662¹

Theresa Williams, Merck Research Laboratories – Calcitonin gene-related peptide antagonists

Robb Webb, Arena Pharmaceuticals – APD 356, A potent and selective 5HT_{2C} agonist is a potential new treatment for obesity

Birgit Masjost, Roche Diagnostics – Structure-based optimization of novel azepane derivatives as PKB selective inhibitors

Thomas Ruckle, Serono Pharmaceutical Research Institute – Identification and development of potent and selective PI3K γ inhibitors

Kirk Stevens, GlaxoSmithKline – Unusual heterocycle synthesis: Routes to Pyrazolo[1,5-a]Pyridine compounds as P38 kinase inhibitors